DNAPrint Genomics (DNAG) Stock Price

DNAPrint Genomics Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Revenue has compounded at 104.8% per year over the past 6 years to 2.43 M USD. DNAPrint Genomics's net margin stands at -507.5%, up from -1,687.1% several years earlier. The stock trades about 100% above its 52-week low.

DNAPrint Genomics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of DNAPrint Genomics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how DNAPrint Genomics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing DNAPrint Genomics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

DNAPrint Genomics Stock Price History
DateDNAPrint Genomics Price
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/20/20250.00 USD
8/19/20250.00 USD
8/18/20250.00 USD
8/15/20250.00 USD
8/14/20250.00 USD
8/13/20250.00 USD
8/12/20250.00 USD
8/11/20250.00 USD
8/8/20250.00 USD
8/7/20250.00 USD
8/6/20250.00 USD
8/5/20250.00 USD
8/4/20250.00 USD
8/1/20250.00 USD
7/31/20250.00 USD
7/30/20250.00 USD
7/29/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

DNAPrint Genomics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2000
33,000.00 USD
0.00 USD
0.00 USD
Jan 1, 2001
14,389.00 USD
2.55 M USD
-2.59 M USD
Jan 1, 2002
184,551.00 USD
2.61 M USD
-3.11 M USD
Jan 1, 2003
709,638.00 USD
6.23 M USD
-7.79 M USD
Jan 1, 2004
785,632.00 USD
3.33 M USD
-3.73 M USD
Jan 1, 2005
1.28 M USD
-4.66 M USD
-8.72 M USD
Jan 1, 2006
2.43 M USD
-8.87 M USD
-12.35 M USD

DNAPrint Genomics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 29, 2026, 3:40 AM
 
REVENUEM USD
REVENUE GROWTH%
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2000200120022003200420052006
–––––1.002.00
––––––100.00
–2.002.006.003.00-4.00-8.00
–––––-400.00-400.00
–-2.00-3.00-7.00-3.00-8.00-12.00
––50.00133.33-57.14166.6750.00
430.4120.8123.2226.1542.47187.98430.41
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales DNAPrint Genomics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue DNAPrint Genomics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare DNAPrint Genomics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares DNAPrint Genomics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against DNAPrint Genomics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

DNAPrint Genomics stock margins

The DNAPrint Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of DNAPrint Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for DNAPrint Genomics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2000
87.88 %
0.00 %
0.00 %
Jan 1, 2001
58.90 %
17,733.35 %
-18,027.01 %
Jan 1, 2002
60.33 %
1,416.20 %
-1,687.13 %
Jan 1, 2003
39.09 %
878.58 %
-1,097.73 %
Jan 1, 2004
35.35 %
424.42 %
-475.41 %
Jan 1, 2005
25.48 %
-365.50 %
-683.33 %
Jan 1, 2006
30.99 %
-364.45 %
-507.54 %

DNAPrint Genomics Stock Revenue, EBIT, Earnings per Share

The DNAPrint Genomics earnings per share therefore indicates how much revenue DNAPrint Genomics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2000
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2001
0.00 USD
0.12 USD
-0.12 USD
Jan 1, 2002
0.01 USD
0.11 USD
-0.13 USD
Jan 1, 2003
0.03 USD
0.24 USD
-0.30 USD
Jan 1, 2004
0.02 USD
0.08 USD
-0.09 USD
Jan 1, 2005
0.01 USD
-0.02 USD
-0.05 USD
Jan 1, 2006
0.01 USD
-0.02 USD
-0.03 USD

DNAPrint Genomics business model & stock analysis

DNAPrint Genomics Inc. was an American company specializing in researching genetic differences and their impact on health, diagnostics, and forensic applications. Founded in Sarasota, Florida in 1997, originally named Genaissance Pharmaceuticals, the company focused on medical research. In 2005, it changed its name to DNAPrint Genomics and shifted its focus to genetic testing development. The company's business model included developing and marketing molecular tests that can reveal an individual's genetic background, providing access to new markets and customers. DNAPrint Genomics offered various product lines for disease diagnosis, including tests for identifying and diagnosing specific diseases like breast cancer, colon cancer, and Alzheimer's. They also provided diagnostics for personalized medicine, matching medication to individuals' genetic predispositions. However, the company gained attention primarily for its forensic applications. They developed a system called DNAWitness, allowing comparison of unknown DNA samples with DNA databases to create offender profiles. The system was used by law enforcement agencies in the U.S. to aid crime investigation and was also involved in international police collaborations. DNAPrint Genomics pursued patents and partnerships with other companies to expand access to new technologies and developments, aiming to position itself in the international market. In 2008, the company announced its discontinuation due to economic reasons, facing complications in selling its DNAWitness system and encountering difficulties in selling its diagnostic tests. Despite having promising products, the company was unable to stabilize its market position and become profitable.

DNAPrint Genomics SWOT Analysis

Strengths

DNAPrint Genomics Inc has several strengths that contribute to its success in the genomics industry. Firstly, the company has a strong patent portfolio, allowing it to protect and monetize its genetic analysis technologies. This provides a competitive advantage and ensures a unique offering to customers.

Secondly, DNAPrint Genomics Inc has a team of highly skilled and experienced scientists and researchers. Their expertise and knowledge in genomics enable the company to develop innovative solutions and stay at the forefront of the industry.

Finally, the company has established strategic partnerships with leading academic institutions and research organizations. These collaborations provide access to cutting-edge research and resources, enhancing DNAPrint Genomics Inc's capabilities and credibility in the market.

Weaknesses

Despite its strengths, DNAPrint Genomics Inc faces some weaknesses that may hinder its growth. One weakness is the high cost associated with the development and commercialization of genetic analysis technologies. This can limit the company's ability to invest in research and development, as well as pricing its products competitively.

In addition, DNAPrint Genomics Inc heavily relies on third-party suppliers for key components and materials. Any disruptions or delays in the supply chain may impact the company's operations and ability to deliver products on time.

Lastly, the genomics industry is highly competitive, with numerous established players and new entrants. DNAPrint Genomics Inc needs to continuously differentiate itself, innovate, and adapt to changes in the industry to stay ahead of the competition.

Opportunities

DNAPrint Genomics Inc has several opportunities to expand its business and market presence. One opportunity lies in the growing demand for personalized medicine. The company can leverage its genetic analysis technologies to offer tailored solutions for healthcare providers and patients, contributing to improved healthcare outcomes.

Another opportunity arises from the increasing adoption of genetic testing for ancestry and genealogy purposes. DNAPrint Genomics Inc can develop and market consumer-focused genetic testing kits, catering to the interest in understanding one's genetic heritage and family history.

Furthermore, the company can explore collaborations with pharmaceutical companies to identify genetic markers for drug response and develop personalized therapies. This can open up new revenue streams and enable DNAPrint Genomics Inc to contribute to the advancement of precision medicine.

Threats

DNAPrint Genomics Inc faces various threats that may impact its operations and financial performance. One significant threat is the evolving regulatory landscape in the genomics industry. Changes in regulations and privacy laws can increase compliance costs and limit the company's ability to collect and use genetic data.

Additionally, there is a risk of intellectual property disputes and patent infringements, especially as the genomics industry grows more competitive. Legal battles can be costly and time-consuming, diverting resources and potentially damaging DNAPrint Genomics Inc's reputation.

Lastly, technological advancements and new discoveries in genomics may render DNAPrint Genomics Inc's current offerings and technologies obsolete. The company needs to continuously invest in research and development to stay ahead of the curve and ensure its relevance in the rapidly evolving genomics landscape.

DNAPrint Genomics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

DNAPrint Genomics historical P/E ratio, EBIT multiple, and P/S ratio

DNAPrint Genomics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

DNAPrint Genomics shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2000
365.24 M Stocks
Jan 1, 2001
20.81 M Stocks
Jan 1, 2002
23.22 M Stocks
Jan 1, 2003
26.15 M Stocks
Jan 1, 2004
42.47 M Stocks
Jan 1, 2005
187.98 M Stocks
Jan 1, 2006
430.41 M Stocks

DNAPrint Genomics stock splits

In DNAPrint Genomics's history, there have been no stock splits.
Price targets and forecasts for DNAPrint Genomics are not yet available.

DNAPrint Genomics shareholder structure

% Name
0.32179%
FCA Corp.
FCA Corp.

DNAPrint Genomics Executives and Management Board

HG

Dr. Hector Gomez

(70)

Chairman of the Board, Chief Medical Officer · since 2002

Compensation757,948.00 USD
TF

Dr. Tony Frudakis

(42)

Chief Scientific Officer, Secretary, Director

Compensation708,487.00 USD
KS

Karen Surplus

(49)

Chief Accounting Officer

Frequently asked questions about DNAPrint Genomics

DNAPrint Genomics Inc. is a company that specializes in genetic research and analysis. Their business model revolves around providing genetic testing services and products for customers in various industries, including pharmaceuticals, healthcare, and forensic science. Through advanced DNA analysis techniques, DNAPrint Genomics Inc. offers personalized genetic testing solutions to help individuals understand their genetic makeup and make informed health decisions. Additionally, the company collaborates with research institutions to develop innovative applications for genetic information. With their expertise in genomics, DNAPrint Genomics Inc. serves as a trusted partner for businesses and individuals seeking reliable genetic testing services and solutions.

All fundamentals and in-depth analysis of DNAPrint Genomics

Our stock analysis for DNAPrint Genomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DNAPrint Genomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

DNAPrint Genomics Stock
DNAPrint Genomics Revenue→
DNAPrint Genomics Stock
DNAPrint Genomics Net Income→
DNAPrint Genomics Stock
DNAPrint Genomics P/E→
DNAPrint Genomics Stock
DNAPrint Genomics P/S→
DNAPrint Genomics Stock
DNAPrint Genomics EBIT→
DNAPrint Genomics Stock
DNAPrint Genomics Dividend→
DNAPrint Genomics Stock
DNAPrint Genomics Directors Dealings→
DNAPrint Genomics Stock
DNAPrint Genomics Stocks→
DNAPrint Genomics Stock
DNAPrint Genomics Market capitalization→
DNAPrint Genomics Stock
DNAPrint Genomics Debt→
DNAPrint Genomics Stock
DNAPrint Genomics Liabilities→
DNAPrint Genomics Stock
DNAPrint Genomics Equity→
DNAPrint Genomics Stock
DNAPrint Genomics AAQS→
DNAPrint Genomics Stock
DNAPrint Genomics Employees→
DNAPrint Genomics Stock
DNAPrint Genomics ROE→
DNAPrint Genomics Stock
DNAPrint Genomics ROA→
DNAPrint Genomics Stock
DNAPrint Genomics ROCE→
DNAPrint Genomics Stock
DNAPrint Genomics News→
DNAPrint Genomics Stock
DNAPrint Genomics Analyst Price Targets→

Health Stocks

DocCheckDizal Pharmaceutical CoDocGoDivi's LaboratoriesDocMode Health TechnologiesDishman Carbogen AmcisDoctorglasses Chain CoDisc MedicineDogwood TherapeuticsDirui Industrial CoDomesco Medical Import Export Joint StockDipna PharmachemAll Stocks A–Z →